share_log

Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study

Dow Jones Newswires ·  Mar 22, 2021 14:15

*DJ Roche: Phase 3 Study Shows Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning

(MORE TO FOLLOW) Dow Jones Newswires

March 22, 2021 02:03 ET (06:03 GMT)

*DJ Roche: Study Met Its Primary Endpoint of Disease-Free Survival at Interim Analysis

(MORE TO FOLLOW) Dow Jones Newswires

March 22, 2021 02:05 ET (06:05 GMT)

*DJ Roche: Tecentriq Showed Statistically Significant Improvement in Disease-Free Survival as Adjuvant Therapy Following Surgery and Chemotherapy

(END) Dow Jones Newswires

March 22, 2021 02:05 ET (06:05 GMT)

DJ Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study

By Cecilia Butini

Roche Holding AG said Monday that a Phase 3 study on its monoclonal antibody drug Tecentriq met the primary endpoint of providing disease-free survival to lung cancer patients.

The Swiss pharmaceutical major said the drug showed a statistically significant improvement in disease-free survival for patients suffering non-small-cell lung cancer after surgery and chemotherapy.

Tecentriq is already approved for five indications for different types of lung cancer in markets around the world, Roche said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

March 22, 2021 02:15 ET (06:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment